Literature DB >> 14982734

Innate immune responses and control of acute simian immunodeficiency virus replication in the central nervous system.

Sheila A Barber1, David S Herbst, Brandon T Bullock, Lucio Gama, Janice E Clements.   

Abstract

Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) can invade the central nervous system (CNS) during acute infection but virus replication is apparently controlled because clinical and pathological manifestations of CNS disease in HIV/SIV-infected individuals usually present later in infection, coincident with immunosuppression and acquired immuno-deficiency syndrome (AIDS). Using an established SIV/macaque model of HIV dementia, the authors recently demonstrated that acute virus replication is down-regulated (to undetectable viral RNA levels) in the brain, but not the periphery, as early as 21 days post inoculation (p.i.). Viral DNA levels in the brain remain constant, suggesting that infected cells persist in the CNS and that replication is inhibited largely at a transcriptional level. In vitro, active replication of HIV in macrophages can be inhibited by treatment with interferon (IFN)beta via a mechanism involving induction of a dominant-negative form of the transcription factor C/EBP (CCAAT/enhancer-binding protein)beta. Because macrophages are the primary cell types infected with HIV/SIV in the CNS and HIV replication in macrophages requires C/EBP sites within the viral long terminal repeat (LTR), the authors considered the possibility that suppression of C/EBP-dependent transcription contributes to the mechanism by which acute HIV/SIV replication is inhibited in the CNS. Here, the authors report that IFNbeta can also inhibit ongoing SIV replication in macaque macrophages in vitro. Further, the authors demonstrate that IFNbeta levels in the brain increase between 7 and 21 days p.i. in parallel with increased expression of the dominant-negative isoform of C/EBPbeta. These results suggest that innate immune responses involving IFNbeta may contribute to the mechanism(s) controlling acute SIV replication in the CNS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982734     DOI: 10.1080/753312747

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  36 in total

1.  Early SIV encephalopathy.

Authors:  B Hurtrel; L Chakrabarti; M Hurtrel; M A Maire; D Dormont; L Montagnier
Journal:  J Med Primatol       Date:  1991-06       Impact factor: 0.667

2.  Retrovirally mediated IFN-beta transduction of macrophages induces resistance to HIV, correlated with up-regulation of RANTES production and down-regulation of C-C chemokine receptor-5 expression.

Authors:  I Cremer; V Vieillard; E De Maeyer
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

3.  Increased macrophage chemoattractant protein-1 in cerebrospinal fluid precedes and predicts simian immunodeficiency virus encephalitis.

Authors:  M C Zink; G D Coleman; J L Mankowski; R J Adams; P M Tarwater; K Fox; J E Clements
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

4.  Interferon-beta directly influences monocyte infiltration into the central nervous system.

Authors:  Sarah Floris; Sigrid R Ruuls; Anne Wierinckx; Susanne M A van der Pol; Ed Döpp; Peter H van der Meide; Christine D Dijkstra; Helga E De Vries
Journal:  J Neuroimmunol       Date:  2002-06       Impact factor: 3.478

5.  Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha.

Authors:  Z Ma; H Qin; E N Benveniste
Journal:  J Immunol       Date:  2001-11-01       Impact factor: 5.422

6.  The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.

Authors:  Kristina Abel; Michelle J Alegria-Hartman; Kristina Rothaeusler; Marta Marthas; Christopher J Miller
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 7.  Regulation of human immunodeficiency virus type 1 gene expression and pathogenesis by CCAAT/enhancer binding proteins in cells of the monocyte/macrophage lineage.

Authors:  Tricia H Hogan; Fred C Krebs; Brian Wigdahl
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

8.  Longitudinal analysis of behavioral, neurophysiological, viral and immunological effects of SIV infection in rhesus monkeys.

Authors:  L H Gold; H S Fox; S J Henriksen; M J Buchmeier; M R Weed; M A Taffe; S Huitrón-Resendiz; T F Horn; F E Bloom
Journal:  J Med Primatol       Date:  1998 Apr-Jun       Impact factor: 0.667

9.  Early viral brain invasion in iatrogenic human immunodeficiency virus infection.

Authors:  L E Davis; B L Hjelle; V E Miller; D L Palmer; A L Llewellyn; T L Merlin; S A Young; R G Mills; W Wachsman; C A Wiley
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

10.  Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines.

Authors:  Yoshihiko Hoshino; Koh Nakata; Satomi Hoshino; Yoshihiro Honda; Doris B Tse; Tatsuo Shioda; William N Rom; Michael Weiden
Journal:  J Exp Med       Date:  2002-02-18       Impact factor: 14.307

View more
  40 in total

Review 1.  Viral and host genetic factors regulating HIV/CNS disease.

Authors:  Jeymohan Joseph; Toby Behar
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

Review 2.  Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction.

Authors:  K Grovit-Ferbas; M E Harris-White
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 3.  CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection.

Authors:  Yujie Liu; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Microbiol       Date:  2009-04       Impact factor: 3.165

4.  Regulation of SIV mac 239 basal long terminal repeat activity and viral replication in macrophages: functional roles of two CCAAT/enhancer-binding protein beta sites in activation and interferon beta-mediated suppression.

Authors:  Shruthi Ravimohan; Lucio Gama; Sheila A Barber; Janice E Clements
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

5.  Simian immunodeficiency virus infection in the brain and lung leads to differential type I IFN signaling during acute infection.

Authors:  Luna Alammar; Lucio Gama; Janice E Clements
Journal:  J Immunol       Date:  2011-03-02       Impact factor: 5.422

Review 6.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

7.  Expansion of a subset of CD14highCD16negCCR2low/neg monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection.

Authors:  Lucio Gama; Erin N Shirk; Julia N Russell; Karina I Carvalho; Ming Li; Suzanne E Queen; Jorge Kalil; M Christine Zink; Janice E Clements; Esper G Kallas
Journal:  J Leukoc Biol       Date:  2012-02-24       Impact factor: 4.962

8.  Tissue-specific interferon alpha subtype response to SIV infection in brain, spleen, and lung.

Authors:  Luna Alammar Zaritsky; Alicia Dery; Wan Yee Leong; Lucio Gama; Janice E Clements
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

9.  CD4-independent entry and replication of simian immunodeficiency virus in primary rhesus macaque astrocytes are regulated by the transmembrane protein.

Authors:  Emily D Overholser; Tahar Babas; M Christine Zink; Sheila A Barber; Janice E Clements
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

10.  Coordinated regulation of SIV replication and immune responses in the CNS.

Authors:  Kenneth W Witwer; Lucio Gama; Ming Li; Christopher M Bartizal; Suzanne E Queen; John J Varrone; Angela K Brice; David R Graham; Patrick M Tarwater; Joseph L Mankowski; M Christine Zink; Janice E Clements
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.